Marvel Biosciences Corp (TSE:MRVL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Marvel Biosciences Corp. has underscored the significance of a study led by scientific board member, Professor David Blum, which links early increases in adenosine A2A receptors in neurons to memory loss in Alzheimer’s disease models. The research, which diverges from traditional focuses on amyloid plaques, points to Tau phosphorylation as a major factor in cognitive deficits, supporting the potential of Marvel’s A2aR antagonist, MB204, as a promising treatment for Alzheimer’s.
For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.